The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.
The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.
This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.
First Single-Dose COVID-19 Vaccine Authorized for Emergency Use
On February 27, 2021, the US Food and Drug Administration (FDA) authorized a single-dose vaccine for emergency use to prevent COVID-19 in individuals 18 years of age and older. The FDA partly based its decision on data from the phase 3 EMSEMBLE trial, which was conducted in eight countries across three continents and included patients infected with emerging viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data from this study demonstrated that the vaccine was 85% effective in preventing severe disease across all geographic regions studied. The level of protection against moderate and severe COVID-19 was 72% in the United States. The vaccine also provided protection against COVID-19-related hospitalization and death, beginning 28 days after vaccination. The Ad.26.COV2.S vaccine is a recombinant vector vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson that uses a human adenovirus to express the SARS-CoV-2 spike protein.
National Institutes of Health (NIH). Janssen investigational COVID-19 vaccine: interim analysis of phase 3 clinical data released. January 29, 2021. Available at www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released Accessed 3/2/2021.
Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—first single-shot vaccine in fight against global pandemic. February 27, 2021. Available at www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic Accessed 3/2/2021.